Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome
Background. Percutaneous coronary intervention (PCI) in the acute coronary syndrome (ACS) setting is associated with a greater probability of device failure. The currently ongoing development of new scaffold technologies has concentrated an effort on improving the PCI outcomes, including the use of...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Interventional Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2022/5223317 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832552748137054208 |
|---|---|
| author | Piotr Rola Adrian Włodarczak Szymon Włodarczak Mateusz Barycki Marek Szudrowicz Magdalena Łanocha Łukasz Furtan Katarzyna Woźnica Jan Jakub Kulczycki Joanna Jaroszewska-Pozorska Michalina Kędzierska Adrian Doroszko Maciej Lesiak |
| author_facet | Piotr Rola Adrian Włodarczak Szymon Włodarczak Mateusz Barycki Marek Szudrowicz Magdalena Łanocha Łukasz Furtan Katarzyna Woźnica Jan Jakub Kulczycki Joanna Jaroszewska-Pozorska Michalina Kędzierska Adrian Doroszko Maciej Lesiak |
| author_sort | Piotr Rola |
| collection | DOAJ |
| description | Background. Percutaneous coronary intervention (PCI) in the acute coronary syndrome (ACS) setting is associated with a greater probability of device failure. The currently ongoing development of new scaffold technologies has concentrated an effort on improving the PCI outcomes, including the use of new biodegradable materials. This pilot study evaluates the performance of a magnesium bioresorbable scaffold (Magmaris, Biotronik, Germany) in comparison to the sirolimus‐eluting bioresorbable polymer stents (BP-SES) (Ultimaster, Terumo, Japan) in the NSTE-ACS setting. Methods. The population of this pilot comprised 362 patients assigned to one of two arms (193-Magmaris vs 169-Ultimaster). The data regarding the primary outcome comprised of death from cardiac causes, myocardial infarction, and stent thrombosis, along with target-lesion failure (TLF) and other clinical events was collected in the 1-yearfollow-up. Results. There were no statistically significant differences in clinical outcomes in the short term (30 days) or in the 1-yearfollow-up between both groups. Conclusion. At 12 months, there were no statistically significant differences between the Magmaris and Ultimaster for composed endpoints or the TLF. |
| format | Article |
| id | doaj-art-f3e4e0e77aff49aaa2901f86fcea99a5 |
| institution | Kabale University |
| issn | 1540-8183 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Interventional Cardiology |
| spelling | doaj-art-f3e4e0e77aff49aaa2901f86fcea99a52025-02-03T05:58:00ZengWileyJournal of Interventional Cardiology1540-81832022-01-01202210.1155/2022/5223317Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical OutcomePiotr Rola0Adrian Włodarczak1Szymon Włodarczak2Mateusz Barycki3Marek Szudrowicz4Magdalena Łanocha5Łukasz Furtan6Katarzyna Woźnica7Jan Jakub Kulczycki8Joanna Jaroszewska-Pozorska9Michalina Kędzierska10Adrian Doroszko11Maciej Lesiak12Witelon Collegium State UniversityWitelon Collegium State UniversityDepartment of CardiologyDepartment of CardiologyDepartment of CardiologyAdalbert’s HospitalDepartment of CardiologyFaculty of Mathematics and Information ScienceDepartment of CardiologyDepartment of CardiologyFaculty of MedicineClinical Department of Internal and Occupational Diseases1st Department of CardiologyBackground. Percutaneous coronary intervention (PCI) in the acute coronary syndrome (ACS) setting is associated with a greater probability of device failure. The currently ongoing development of new scaffold technologies has concentrated an effort on improving the PCI outcomes, including the use of new biodegradable materials. This pilot study evaluates the performance of a magnesium bioresorbable scaffold (Magmaris, Biotronik, Germany) in comparison to the sirolimus‐eluting bioresorbable polymer stents (BP-SES) (Ultimaster, Terumo, Japan) in the NSTE-ACS setting. Methods. The population of this pilot comprised 362 patients assigned to one of two arms (193-Magmaris vs 169-Ultimaster). The data regarding the primary outcome comprised of death from cardiac causes, myocardial infarction, and stent thrombosis, along with target-lesion failure (TLF) and other clinical events was collected in the 1-yearfollow-up. Results. There were no statistically significant differences in clinical outcomes in the short term (30 days) or in the 1-yearfollow-up between both groups. Conclusion. At 12 months, there were no statistically significant differences between the Magmaris and Ultimaster for composed endpoints or the TLF.http://dx.doi.org/10.1155/2022/5223317 |
| spellingShingle | Piotr Rola Adrian Włodarczak Szymon Włodarczak Mateusz Barycki Marek Szudrowicz Magdalena Łanocha Łukasz Furtan Katarzyna Woźnica Jan Jakub Kulczycki Joanna Jaroszewska-Pozorska Michalina Kędzierska Adrian Doroszko Maciej Lesiak Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome Journal of Interventional Cardiology |
| title | Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome |
| title_full | Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome |
| title_fullStr | Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome |
| title_full_unstemmed | Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome |
| title_short | Magnesium Bioresorbable Scaffold (BRS) Magmaris vs Biodegradable Polymer DES Ultimaster in NSTE-ACS Population—12-Month Clinical Outcome |
| title_sort | magnesium bioresorbable scaffold brs magmaris vs biodegradable polymer des ultimaster in nste acs population 12 month clinical outcome |
| url | http://dx.doi.org/10.1155/2022/5223317 |
| work_keys_str_mv | AT piotrrola magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome AT adrianwłodarczak magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome AT szymonwłodarczak magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome AT mateuszbarycki magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome AT marekszudrowicz magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome AT magdalenałanocha magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome AT łukaszfurtan magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome AT katarzynawoznica magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome AT janjakubkulczycki magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome AT joannajaroszewskapozorska magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome AT michalinakedzierska magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome AT adriandoroszko magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome AT maciejlesiak magnesiumbioresorbablescaffoldbrsmagmarisvsbiodegradablepolymerdesultimasterinnsteacspopulation12monthclinicaloutcome |